JP2012513216A - Ｘｍｒｖの検出方法 - Google Patents
Ｘｍｒｖの検出方法 Download PDFInfo
- Publication number
- JP2012513216A JP2012513216A JP2011543647A JP2011543647A JP2012513216A JP 2012513216 A JP2012513216 A JP 2012513216A JP 2011543647 A JP2011543647 A JP 2011543647A JP 2011543647 A JP2011543647 A JP 2011543647A JP 2012513216 A JP2012513216 A JP 2012513216A
- Authority
- JP
- Japan
- Prior art keywords
- xmrv
- nucleotide sequence
- forward primer
- reverse primer
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000101098 Xenotropic MuLV-related virus Species 0.000 title claims abstract description 327
- 238000001514 detection method Methods 0.000 title claims abstract description 36
- 238000003752 polymerase chain reaction Methods 0.000 claims abstract description 93
- 238000000034 method Methods 0.000 claims abstract description 84
- 210000002307 prostate Anatomy 0.000 claims abstract description 50
- 238000003753 real-time PCR Methods 0.000 claims abstract description 32
- 210000002700 urine Anatomy 0.000 claims abstract description 25
- 210000000416 exudates and transudate Anatomy 0.000 claims abstract description 9
- 239000002773 nucleotide Substances 0.000 claims description 244
- 125000003729 nucleotide group Chemical group 0.000 claims description 244
- 239000000523 sample Substances 0.000 claims description 176
- 230000000295 complement effect Effects 0.000 claims description 152
- 206010060862 Prostate cancer Diseases 0.000 claims description 70
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 64
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 19
- 210000001519 tissue Anatomy 0.000 claims description 18
- 239000012530 fluid Substances 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 5
- 238000003757 reverse transcription PCR Methods 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 238000001502 gel electrophoresis Methods 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 2
- 210000004908 prostatic fluid Anatomy 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 abstract description 25
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 abstract description 16
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 abstract description 16
- 102000039446 nucleic acids Human genes 0.000 abstract description 16
- 108020004707 nucleic acids Proteins 0.000 abstract description 16
- 238000004458 analytical method Methods 0.000 abstract description 5
- 241000714177 Murine leukemia virus Species 0.000 abstract description 4
- 239000013615 primer Substances 0.000 description 245
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 83
- 108020004414 DNA Proteins 0.000 description 60
- 230000003321 amplification Effects 0.000 description 34
- 238000003199 nucleic acid amplification method Methods 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 15
- 238000003556 assay Methods 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 12
- 102000053602 DNA Human genes 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 101001080057 Homo sapiens 2-5A-dependent ribonuclease Proteins 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000011471 prostatectomy Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000013068 control sample Substances 0.000 description 6
- 208000020735 familial prostate carcinoma Diseases 0.000 description 6
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 108010006785 Taq Polymerase Proteins 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000002987 primer (paints) Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 4
- 239000013614 RNA sample Substances 0.000 description 4
- 208000005074 Retroviridae Infections Diseases 0.000 description 4
- 108010020713 Tth polymerase Proteins 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001663880 Gammaretrovirus Species 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 238000010802 RNA extraction kit Methods 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 239000007984 Tris EDTA buffer Substances 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000012864 cross contamination Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000007857 nested PCR Methods 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000001625 seminal vesicle Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 201000010653 vesiculitis Diseases 0.000 description 3
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 101150077651 VP35 gene Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 108010068698 spleen exonuclease Proteins 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100017043 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HIR3 gene Proteins 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 108010001244 Tli polymerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- -1 affinity tags (eg Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019689 luncheon sausage Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229910001437 manganese ion Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229910052755 nonmetal Chemical class 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20355608P | 2008-12-23 | 2008-12-23 | |
| US61/203,556 | 2008-12-23 | ||
| PCT/US2009/069244 WO2010075414A2 (en) | 2008-12-23 | 2009-12-22 | Method for detection of xmrv |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012513216A true JP2012513216A (ja) | 2012-06-14 |
| JP2012513216A5 JP2012513216A5 (OSRAM) | 2013-01-17 |
Family
ID=42096470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011543647A Pending JP2012513216A (ja) | 2008-12-23 | 2009-12-22 | Ｘｍｒｖの検出方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100184015A1 (OSRAM) |
| EP (1) | EP2382326A2 (OSRAM) |
| JP (1) | JP2012513216A (OSRAM) |
| CA (1) | CA2748117A1 (OSRAM) |
| WO (1) | WO2010075414A2 (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019521695A (ja) * | 2016-07-29 | 2019-08-08 | ジュノー セラピューティクス インコーポレイテッド | 複製可能ウイルスの存在または非存在を評価するための方法 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007012361A (es) * | 2005-04-07 | 2008-02-11 | Cleveland Clinic Foundation | Gamaretrovirus asociado con cancer. |
| EP2448960A1 (en) | 2009-06-30 | 2012-05-09 | Abbott Laboratories | Markers of xmrv infection and uses thereof |
| US9410189B2 (en) * | 2010-04-30 | 2016-08-09 | Co-Diagnostics, Inc. | Methods of preventing non-specific reactions of nucleotide sequences |
| CA2803011C (en) * | 2010-07-16 | 2019-12-03 | Tocagen Inc. | Retrovirus detection |
| WO2012024513A2 (en) * | 2010-08-18 | 2012-02-23 | Abbott Laboratories | Molecular detection of xmrv infection |
| WO2012024518A1 (en) * | 2010-08-18 | 2012-02-23 | Abbott Laboratories | Molecular detection of xmrv infection |
| WO2012030856A2 (en) * | 2010-08-30 | 2012-03-08 | Gen-Probe Incorporated | Compositions, methods and reaction mixtures for the detection of xenotropic murine leukemia virus-related virus |
| GB201019043D0 (en) | 2010-11-10 | 2010-12-22 | Protea Biopharma N V | Use of 2',5'-oligoadenylate derivative compounds |
| US20130065222A1 (en) * | 2011-08-30 | 2013-03-14 | Gen-Probe Incorporated | Compositions, methods and reaction mixtures for the detection of murine leukemia virus-related virus |
| CN102337359B (zh) * | 2011-11-02 | 2014-02-19 | 舒泰神（北京）生物制药股份有限公司 | 用于检测小鼠白血病病毒的引物、探针及其方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008538494A (ja) * | 2005-04-07 | 2008-10-30 | ザ クリーブランド クリニック ファウンデーション | 癌と関連するガンマレトロウイルス |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10306234B4 (de) | 2003-02-04 | 2009-09-17 | Daimler Ag | Verfahren zur Luftversorgung einer Brennstoffzelle und Vorrichtung zur Durchführung des Verfahrens |
| US20110151431A1 (en) * | 2009-06-18 | 2011-06-23 | Whittemore Peterson Institute For Neuro-Immune Disease | Detection of xenotropic murine leukemia virus |
| EP2448960A1 (en) * | 2009-06-30 | 2012-05-09 | Abbott Laboratories | Markers of xmrv infection and uses thereof |
-
2009
- 2009-12-22 JP JP2011543647A patent/JP2012513216A/ja active Pending
- 2009-12-22 CA CA2748117A patent/CA2748117A1/en not_active Abandoned
- 2009-12-22 US US12/645,181 patent/US20100184015A1/en not_active Abandoned
- 2009-12-22 EP EP09804357A patent/EP2382326A2/en not_active Withdrawn
- 2009-12-22 WO PCT/US2009/069244 patent/WO2010075414A2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008538494A (ja) * | 2005-04-07 | 2008-10-30 | ザ クリーブランド クリニック ファウンデーション | 癌と関連するガンマレトロウイルス |
Non-Patent Citations (1)
| Title |
|---|
| JPN6014020719; ＪＯＵＲＮＡＬ ＯＦ ＶＩＲＯＬＯＧＹ ｖｏｌ．８２ ｎｏ．２０, 200810, ｐｐ．９９６４-９９７７ * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019521695A (ja) * | 2016-07-29 | 2019-08-08 | ジュノー セラピューティクス インコーポレイテッド | 複製可能ウイルスの存在または非存在を評価するための方法 |
| JP7483373B2 (ja) | 2016-07-29 | 2024-05-15 | ジュノー セラピューティクス インコーポレイテッド | 複製可能ウイルスの存在または非存在を評価するための方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010075414A2 (en) | 2010-07-01 |
| US20100184015A1 (en) | 2010-07-22 |
| CA2748117A1 (en) | 2010-07-01 |
| WO2010075414A3 (en) | 2010-10-07 |
| EP2382326A2 (en) | 2011-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012513216A (ja) | Ｘｍｒｖの検出方法 | |
| US7101663B2 (en) | PCR method | |
| JP7766398B2 (ja) | マイクロサテライト配列中の突然変異を検出する方法 | |
| AU2002247248A1 (en) | PCR method | |
| JP2018046818A (ja) | プロセシングしていない試料において、関心対象の核酸の量を決定するための方法 | |
| AU2009243522A1 (en) | Diagnosing or predicting the course of breast cancer | |
| CN113832258A (zh) | 使用衰减型探针的核糖核酸扩增和检测 | |
| KR102648647B1 (ko) | 짧은 호모폴리머릭 반복서열의 개선된 검출법 | |
| JP7045702B2 (ja) | リアルタイムで核酸を検出するための一本鎖核酸及びこれを用いた検出方法 | |
| AU2020445677A1 (en) | Tumor detection reagent and kit | |
| CN115176031B (zh) | 简化的多核苷酸序列检测方法 | |
| CN103562411B (zh) | 细环病毒诊断学 | |
| CN118451202A (zh) | 一种肿瘤检测方法及应用 | |
| EP1757705B1 (en) | Intraoperative lymph node assay | |
| CN102171369A (zh) | 存活蛋白mRNA的测定方法 | |
| US20150307923A1 (en) | Megasphaera cerevisiae system process control (spc) primers, probes, and methods | |
| KR20200029958A (ko) | 실시간 중합효소 연쇄반응과 융해곡선 분석법을 이용한 구강암 관련 hpv 스크리닝 및 16번 타입 정성 검사 방법 | |
| WO2024195263A1 (ja) | 遺伝子のＣｐＧのメチル化レベルを測定する方法 | |
| AU2007221860A1 (en) | PCR method | |
| HK1130514A (en) | Diagnosing or predicting the course of breast cancer | |
| JP2008517626A (ja) | 乳房細胞を検出するための核酸プライマー及びプローブ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121122 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121122 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140521 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140818 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140825 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140911 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140919 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141216 |